Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $102000.0.

  • Zenas BioPharma's Change in Accured Expenses rose 53750.0% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 2741.76%. This contributed to the annual value of $22.1 million for FY2024, which is 72015.18% up from last year.
  • Per Zenas BioPharma's latest filing, its Change in Accured Expenses stood at $102000.0 for Q3 2025, which was up 53750.0% from $16.3 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Change in Accured Expenses high stood at $16.3 million for Q2 2025, and its period low was -$11.2 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $2.4 million (2023), whereas its average is $3.8 million.
  • The largest annual percentage gain for Zenas BioPharma's Change in Accured Expenses in the last 5 years was 53750.0% (2025), contrasted with its biggest fall of 84433.33% (2025).
  • Zenas BioPharma's Change in Accured Expenses (Quarter) stood at $3.2 million in 2023, then skyrocketed by 267.0% to $11.9 million in 2024, then tumbled by 99.14% to $102000.0 in 2025.
  • Its Change in Accured Expenses was $102000.0 in Q3 2025, compared to $16.3 million in Q2 2025 and -$11.2 million in Q1 2025.